Page 16 - 2021 Taiwan Food and Drug Administration Annual Report
P. 16

WULDOV   FOLQLFDO  WULDOV   PDUNHWLQJ  DSSOLFDWLRQ      timely manner. These measures would also
PDQXIDFWXULQJ  WR  PDUNHWLQJ   DQG  YDULRXV             facilitate the development of biotechnology
JRRG  RSHUDWLQJ  SUDFWLFHV   HWF    PXVW  EH  IRO-      industry in Taiwan and create a win-win situ-
ORZHG  7R  HQVXUH  WKH  VDIHW\  RI  WKH  SXEOLF         DWLRQ  DPRQJ  SDWLHQWV   SKDUPDFHXWLFDO  LQGXV-
                                                        tries and the government.
TFDA continues to reinforce the quality
                                                        II. Controlled drug management
management policy throughout the drug                      framework

life-cycle (Figure 1-5) through harmoniza-                 Controlled drugs refer to addictive narcotic
WLRQ  ZLWK  LQWHUQDWLRQDO  UHJXODWRU\  VWDQGDUGV        GUXJV   SV\FKRWURSLF  GUXJV   DQG  RWKHU  GUXJV 
GLJLWDO  GUXJ  PDQDJHPHQW   VWDQGDUGL]DWLRQ             that require regulations and may only be used
RI  TXDOLW\  DQG  VDIHW\  VXSHUYLVLRQ   EDQ  DQG        for medical and scientific purposes. If used
LQVSHFWLRQ RI LOOHJDO GUXJV  GUXJ EXVLQHVV RS-          LPSURSHUO\  RU  LOOHJDOO\   WKH\  FDQ  HDVLO\  FDXVH 
HUDWRUV DQG SURGXFW FLUFXODWLRQ PDQDJHPHQW              health hazards to the people.

etc. All of these measures are ensuring the                 According to the “Controlled Drugs
VDIHW\   H൶FDF\  DQG  TXDOLW\  RI  GUXJV   VR  WKDW 

those in need can obtain the medicines in a

   Product   Pre-clinical     Clinical                    Listing      Production        Marketing
Development    Testing          Trial                   application

             Good Laboratory  Good Clinical             Pre-marketing  Post-market
              Practice (GLP)  Practice (GCP)                Review     Surveillance

                                                           Approval                  Post Marketing
                                                                                     Change Control
                                  TFDA / Institutional
                              Review Board (TFDA/IRB)

Production Source Control     Good Manufacturing Practice (GMP)/Good Tissue Practice (GTP)

Product Risk Control                                    Risk Evaluation & Mitigation Strategies / Risk
                                                                 Management Plan (REMS/RMP)

             General / Case-Specific Consultation                      ADR & defective product
                                                                                 reporting

                                                                       Good Pharmacovigilance
                                                                             Practice (GPvP)

                                                                       Good Distribution Practice (GDP)
                                                                           Regulations Governing the
                                                                           Trace and Track System for
                                                                                Medicinal Products

                                                                         Good Pharmacy Practice (GPP)

                                                                       Pharmaceutical Care / Safety
                                                                           Medication Education

                                     Figure1-5 Life cycle management structure of drugs
14
   11   12   13   14   15   16   17   18   19   20   21